Michael Gorley Sells 30,000 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

Posted by Francis Steltz on Jul 3rd, 2026

ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) Director Michael Gorley sold 30,000 shares of ASP Isotopes stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $6.27, for a total transaction of $188,100.00. Following the completion of the transaction, the director owned 87,908 shares of the company’s stock, valued at $551,183.16. This trade represents a 25.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

ASP Isotopes Stock Down 8.8%

NASDAQ ASPI opened at $5.63 on Friday. The stock’s 50 day simple moving average is $6.25 and its 200 day simple moving average is $5.90. ASP Isotopes Inc. has a one year low of $3.92 and a one year high of $14.49. The firm has a market cap of $708.82 million, a PE ratio of -2.71 and a beta of 3.51. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.39 and a quick ratio of 4.37.

ASP Isotopes (NASDAQ:ASPI – Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. The firm had revenue of $8.36 million during the quarter, compared to the consensus estimate of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ASPI. State of Wyoming bought a new stake in shares of ASP Isotopes during the first quarter worth approximately $29,000. Quantbot Technologies LP bought a new position in ASP Isotopes in the third quarter valued at approximately $34,000. BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after acquiring an additional 2,548 shares during the last quarter. Stephens Inc. AR acquired a new stake in ASP Isotopes during the 1st quarter worth $44,000. Finally, Broadhurst Jeffrey B acquired a new stake in ASP Isotopes during the 1st quarter worth $44,000. Institutional investors own 16.80% of the company’s stock.

Analyst Upgrades and Downgrades

ASPI has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.00.

Read Our Latest Report on ASP Isotopes

ASP Isotopes Company Profile

(Get Free Report)

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.